Clinical Trial

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out more about the effectiveness of Tadalafil in improving hemodynamic capabilities, endothelial function, and end-organ function in patients who have previously undergone a Fontan Palliation.
Protocol Amendment History 1 change
notable Enrollment reduced: 80 -> 42 participants 2026-08-14
Trial Details
NCT Number NCT05206955
Lead Sponsor Mayo Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Fontan Palliation
Enrollment 42 participants
Start Date 2022-09-16
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-13